Protara Therapeutics, Inc. 8-K Filing

Ticker: TARA · Form: 8-K · Filed: Nov 19, 2025 · CIK: 1359931

Protara Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyProtara Therapeutics, Inc. (TARA)
Form Type8-K
Filed DateNov 19, 2025
Pages5
Reading Time6 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 8-K filing submitted by Protara Therapeutics, Inc. (ticker: TARA) to the SEC on Nov 19, 2025.

What are the key financial figures in this filing?

Key dollar amounts include: $0.001 (ch registered Common Stock, par value $0.001 per share TARA The Nasdaq Global Ma).

How long is this filing?

Protara Therapeutics, Inc.'s 8-K filing is 5 pages with approximately 1,434 words. Estimated reading time is 6 minutes.

Where can I view the full 8-K filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 1,434 words · 6 min read · ~5 pages · Grade level 13.1 · Accepted 2025-11-19 09:15:36

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share TARA The Nasdaq Global Ma

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On November 19, 2025, Protara Therapeutics, Inc. (the "Company" or "Protara") posted an investor presentation (the "Investor Presentation") to the "Investors—Events and Presentations" section of the Company's website at http://www.protaratx.com and posted a press release (the " Press Release") to the "Investors—Press Releases" section of the Company's website at www.protaratx.com. The Investor Presentation and Press Release will be used in connection with a conference call and webcast today, November 19, 2025, at 8:30 am ET, to review the clinical data on the ongoing Phase 2 STARBORN-1 trial program. A copy of the Investor Presentation is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. A copy of the Press Release is furnished herewith as Exhibit 99.2 to this Current Report on Form 8-K. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. On November 19, 2025, the Company announced interim results from its ongoing Phase 2 STARBORN-1 clinical trial of TARA-002 in pediatric patients with Lymphatic Malformations ("LMs") during a conference call. The Company also issued the Press Release in connection with the announcement of such results. The Company reported data that highlights the potential of intracystic injection of TARA-002 in pediatric patients with LMs in its Phase 2 STARBORN-1 clinical trial, which is assessing TARA-002, the Company's investigational cell-based therapy, in patients with macrocystic and mixed-cystic LMs. The interim analysis includes a total of 12 patients who enrolled in the trial and received more than one dose of TARA-002 as of the November 12, 2025 data cutoff. The dataset includes eight patients who were evaluable at eight weeks, two patients who withdrew prior to the eight-week assessment, and two patients remaining in dosing as of the data cutoff on November 12, 2025. Assessment of efficacy is based on the proportion of participants with macrocystic and mixed-cystic LMs who demonstrate clinical success, defined as having either a complete response (90% to 100% reduction from baseline in total LM volume) or substantial response (60% to less than 90% reduction in total LM volume) as measured by axial imaging or via investigator assessment (physical exam, visual inspection and ultrasound). Of the eight patients who were evaluable, the majority (7/8) achieved clinical success with one or two doses. One patient, who presented with a 1,739 ml macrocystic LM, required all four doses, and achieved a complete response. 80% (8/10) of patients that completed treatment achieved clinical success. 100% (8/8) of patients who completed the eight-week response assessment achieved clinical success. 83% (5/6) of macrocystic patients achieved a complete response and the other patient achieved a substantial response. The only mixed-cystic patient achieved a complete

Forward-Looking Statements

Forward-Looking Statements matters that are not historical facts are "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "designed," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words or expressions referencing future events, conditions or circumstances that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include but are not limited to, statements regarding Protara's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: Protara's business strategy, including its development plans for its product candidates and plans regarding the timing or outcome of existing or future clinical trials (including the timing of any particular phases of such trials and the timing of the announcement of any data produced during such trials or phases thereof); statements related to expectations regarding interactions with the U.S. Food and Drug Administration (FDA); Protara's financial position; statements regarding the anticipated safety or efficacy of Protara's product candidates; and Protara's outlook for the remainder of the year and future periods. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that contribute to the uncertain nature of the forward-looking statements include: risks that Protara's financial guidance may not be as expected, as well as risks and uncertainties associated with: Protara's development programs, including the initiation and completion of non-clinical studies and clinical trials and the timing of required filings with the FDA

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Investor Presentation, dated November 19, 2025. 99.2 Press Release, dated November 19, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 19, 2025 Protara Therapeutics, Inc. By: /s/ Patrick Fabbio Patrick Fabbio Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.